Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TNG462 + pembrolizumab
- Development stage
- Phase 2
- Lead developer
- Tango Therapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
TNG462 + pembrolizumab is a combination therapy under investigation for advanced or metastatic solid tumors characterized by homozygous MTAP deletion. TNG462 is a selective, orally administered MTA-cooperative PRMT5 inhibitor that induces synthetic lethality in cancer cells lacking MTAP, resulting in preferential cytotoxicity against tumor cells while sparing normal tissue. Pembrolizumab is an immune checkpoint inhibitor targeting PD-1, used to enhance anti-tumor T cell responses. The combination aims to exploit the dependence of MTAP-deleted tumors on PRMT5 activity while also leveraging the immunotherapeutic effects of PD-1 blockade. This combination is being evaluated in a Phase 1/2 multi-center, open-label clinical trial for efficacy, safety, tolerability, and anti-neoplastic activity across multiple MTAP-deleted cancer types, including non-small cell lung cancer (NSCLC), mesothelioma, pancreatic ductal adenocarcinoma, sarcoma, and other solid tumors[1][2][3].
- Other names
- TNG462 + pembrolizumab
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)PRMT5 (Protein arginine N-methyltransferase 5)
Beyond the preview
Go deeper on TNG462 + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TNG462 + pembrolizumab.